Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2011, Article ID 703031, 7 pages
Research Article

Apelin Serum Level in Egyptian Patients with Chronic Hepatitis C

1Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abassia, Cairo 11566, Egypt
2Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt

Received 8 May 2011; Revised 8 July 2011; Accepted 25 August 2011

Academic Editor: Giamila Fantuzzi

Copyright © 2011 Hala O. El-Mesallamy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. Highlighting the apelin system would present a new therapeutic target for liver disease. Apelin; endogenous ligand for the orphan receptor APJ, was recently suggested to be associated with fibrosis progression and cirrhosis in addition to insulin resistance (IR) and inflammation. The present study was conducted to evaluate blood apelin level changes among 73 chronic hepatitis C (CHC) Egyptian patients and if associated with body mass index (BMI), IR, and tumor necrosis factor-alpha (TNF-α). Serum apelin levels were significantly higher in patients with CHC with median value (3.25) when compared with controls (1.11), at , with significant apelin variations among asymptomatic carriers (ASC), fibrosis, and cirrhosis patients, and also among obese and nonobese patients. Multiple regression analysis depicted that BMI, triglycerides, and total cholesterol were independent correlation factors to apelin levels, whereas TNF-α was found to be significantly negatively correlated to adjusted apelin in CHC patients ( , ). IR was positively correlated to adjusted apelin in CHC patients ( , ). Conclusion. Apelin level varies among stages of CHC, which may contribute to fibrosis progression. In addition, obesity and IR could act as comorbid factors affecting apelin level in patients with CHC.